Dr. Wermeling’s primary area of research involves formal drug development in an academic setting sponsored by pharmaceutical industry, University/faculty sponsorship, or of products of his own design. A goal for this development process, particularly for UK-held intellectual property, is to evolve the development into independent businesses that form in the Lexington community. Specific development programs include the design, formulation, manufacturing and clinical testing of drugs and delivery systems designed for intranasal drug administration leading toward a new drug application and FDA approval for marketing.

Wermeling Daniel P. (2015). Review of naloxone safety for opioid overdose: practical considerations for new technology and expanded public access. . Therapeutic Advances in Drug Safety, 6 , 20-31. Wermeling Daniel P, Martin Catherine. (2015). Prescribe Naloxone to Reduce Opioid Overdose Mortality. American Academy of Clinical Adolescent Psychiatry, Wermeling Daniel P, Robinson Amanda. (2014). Intranasal Administration of Naloxone Injection for the Treatment of Opioid Overdose. . American Journal of Health System Pharmacy, 71, Bailey A M, Wermeling Daniel P. (2014). Naloxone for opioid overdose prevention: pharmacists' role in community-based practice settings. The Annals of pharmacotherapy, 48(5), 601-6. Bailey Abby M, Wermeling Daniel P. (2014). Naloxone for opioid overdose prevention: pharmacists' role in community-based practice settings. The Annals of pharmacotherapy, 48(5), 601-6. Hewlett L, Wermeling Daniel P. (2013). Survey of naloxone legal status in opioid overdose prevention and treatment. Journal of opioid management, 9(5), 369-77. Wermeling Daniel P. (2013). A response to the opioid overdose epidemic: naloxone nasal spray . Drug Delivery and Translational Research/Springer Science & Business Media , 3(1), 63-74. Lile Joshua Anthony, Babalonis Shanna, Emurian Cleeve, Martin Catherine A, Wermeling Daniel P, Kelly Thomas H. (2011). Comparison of the behavioral and cardiovascular effects of intranasal and oral d-amphetamine in healthy human subjects. Journal of Clinical Pharmacology, 51(6), 888-898. Martin Catherine A, Lile Joshua Anthony, Babalonis S, Emurian C, Wermeling Daniel P, Kelly Thomas H. (2011). Comparison of the behavioral and cardiovascular effects of intranasal and oral d-amphetamine in healthy human subjects. Journal of Clinical Pharmacology, 51, 888-898. Wermeling Daniel P. (2010). Opioid Harm Reduction Strategies: Focus on Expanded Access to Intranasal Naloxone. Pharmacotherapy/Pharmacotherapy Publications Inc., 30(7), 627-631.